The Phillies, Direct Relief International and Teva Respiratory Team to Promote Asthma Awareness
- Asthma Awareness Event Open to the Public -
PHILADELPHIA, June 22 /PRNewswire/ -- The Phillie Phanatic, 2008 World Series trophy and Phillies Ballgirls will be on hand at the Haddington Health Center, a part of Spectrum Health Services, to promote asthma awareness. Stop by for photos with T...
Statement by Teva Pharmaceuticals on Eshoo-Barton Bill
NORTH WALES, Pa., March 17 /PRNewswire-USNewswire/ -- Teva
Pharmaceuticals USA, the leading generic pharmaceutical company, today released the following statement by Debra Barrett, Senior Vice President of Government Affairs on the introduction of a biogenerics bill by Representatives Anna Eshoo a...
Barr Shareholders Approve Pending Teva Acquisition
MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL ) today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva
Pharmaceuticals Industries Ltd. (Nasdaq: TEVA
Fitness and Figure Professionals Kirsten Nicewarner and Michelle Adams to Represent GNC at Vail's Teva Mountain Games
Plus, see the GNC Ultimate Mountain Challenge!
PITTSBURGH, June 3 /PRNewswire/ -- GNC will host fitness and figure
competitors Kirsten Nicewarner and Michelle Adams at the 2008 Teva
Games Thursday through Sunday in Vail Valley, Colo. Both International
Federation of Bodyb...
GPhA Announces 2008-2009 Executive Committee; Teva North America's Bill Marth Elected as Chairman of the Board
BOCA RATON, Fla., Feb. 12 /PRNewswire/ -- The Generic Pharmaceutical
Association (GPhA) Board of Directors today named the members of its newly
elected Executive Committee and announced the election of William Marth,
President and CEO of Teva
North America, to serve as its Chairman for 2008-
OrthoLite Joins the Teva U.S. Mountain Running Team
Signed as official insole for Mountain Running Team
AMHERST, Mass., Feb. 11 /PRNewswire/ -- OrthoLite recently signed on as
the official insole of the 2008 Teva
U.S. Mountain Running Team. OrthoLite
is the world's leading supplier of open cell foam insoles in the
performance and foot...
Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Teva's Launch of Generic Pantoprazole
- Settlement Possible; Significant Obstacles Remain -
COLLEGEVILLE, Pa., Jan. 21 /PRNewswire-FirstCall/ -- Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that it
has agreed with Teva
Pharmaceuticals USA, Inc. to extend the standstill
period previously announ...
Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector
Barrett, David Schlotterbeck Named Vice Chairmen
DUBLIN, Ohio, Jan. 10 /PRNewswire-FirstCall/ -- Cardinal Health, a
global provider of products and services that improve the safety and
productivity of health care, today announced that George S. Barrett, chief
executive officer (CEO...
AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva
WILMINGTON, Del., Nov. 25 /PRNewswire-FirstCall/ -- AstraZeneca today
announced it has entered into a settlement agreement in its Pulmicort Respules
patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly
owned subsidiary of Teva
The agreement sett...
US Court Allows Teva to Deliver Disputed Drug: Novartis
A US court has authorised Israeli generic medicines group Teva
to resume deliveries of a blood pressure drug despite a patent lawsuit by Novartis, the Swiss pharmaceutical group said on Tuesday . A US federal court judge in New Jersey rejected on Monday a request from Novartis to stop Teva
Teva in Medical Technology
Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)
SWARTZ CREEK, Mich., Oct. 10 /PRNewswire/ -- Diplomat Specialty
Pharmacy announced today that Teva
Neuroscience has selected Diplomat
Specialty Pharmacy to be one of only three sites to participate in a large
scale, national Therapy Optimization Study for Multiple Sclerosis (TOP MS).
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals,
Inc. (Nasdaq: IDEV ) today announced that it has signed a development,
license and commercialization agreement with Teva
Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously
UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
...ug designation in the U.S. and in Europe. Gamida Cell's current
shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare
Pharmaceuticals, Amgen, Denali Ventures and Auriga Ventures.
UPMC Media Relations
CEL-SCI Corporation Releases Letter to Shareholders
We signed a Multikine(R) licensing agreement with teva
Pharmaceuticals , one of the top 20 pharmaceutical companies in the world. teva
will participate in and pay for part of the Multikine Phase III trial.
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
...xecutive Officer of Isis. "ATL/TV1102 and ATL's strategic relationship
to move the drug forward further validates our business strategy.
ATL has s... a potential treatment for
prostate cancer. ATL/TV1102 has been licensed to teva
About Isis Pharmaceuticals, Inc.
Isis Pharmaceuticals Conference Call Notice
...esults of the TV-1102 clinical trial
and the ATL / teva
/ Isis relationship.
-- ATL and teva
announced clinical data on TV-1102 demonstrating
p...se.com.au/_home.asp to view the release titled: teva
Pharmaceuticals & Antisense Therapeutics Announce ...
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease
...d spun out 65
companies. Yissum's business partners span the globe and include companies
such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel, teva
Statement on Cautionary Factors
Except for the historical information presented herein, matters
discussed may constitute forward-lo...
BioLineRx Presents Data on BL-1040 at Cardiovascular
Revascularization Therapies Conference Demonstrating Potential to
Reduce Deterioration of Infarcted Heart Tissue and Maintain
companies seeking their next blockbuster drugs. The Company was
founded in 2003 by leaders in the Israeli life science arena
Pharmaceuticals Ltd, Giza, Pitango, Hadasit and the
Jerusalem Development Authority. For more information, please visit
First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone
Was More Cost-Effective Than Interferon Beta Therapies for
Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
...ntis. In North
America, COPAXONE(R) is marketed by teva
Neuroscience, Inc., which
is a subsidiary of teva
Pharmaceutical Industries Ltd
(NASDAQ:TEVA). COPAX...trademark of Teva
Pharmaceutical Industries Ltd.
Pharmaceutical Industries Ltd., headquartered in I...
Data Published in Neurology Showed That Higher Dose of Copaxone
Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
...ASDAQ:TEVA). In Europe,
COPAXONE(R) is marketed by teva
Pharmaceutical Industries Ltd. and
sanofi-aventis....trademark of Teva
Pharmaceutical Industries Ltd.
Pharmaceutical Industries Ltd., headquartered in I...competing generic equivalents, the extent to which teva
obtain U.S. market exclusivity for certain of ...
Teva in Biological News
Teva in Biological Technology
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
REHOVOT, Israel and JERSEY CITY, New Jersey, January 8
/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading
developer of microRNA-based molecular diagnostics, announced today it has
signed an exclusive distribution agreement with Teva
Industries Ltd. Under...
Codexis, Teva in Licensing Agreement Final
REDWOOD CITY, Calif., Jan. 7 /PRNewswire/ -- Codexis, Inc. today announced
a licensing agreement with Teva
Pharmaceutical Industries Ltd., to produce an
important publicly-undisclosed generic product, using a proprietary Codexis
biocatalyst. Teva, the largest generic drug manufacturer in the ...
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM ) announced today that it has entered into an exclusive licensing
agreement with Teva
Pharmaceutical Industries Ltd. (Teva), a leading global
pharmaceutical company, under which CEL-SCI has granted Teva
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
TOKYO and WOODCLIFF LAKE, N.J., March 28 /PRNewswire/ -- Eisai Co.,
Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today
announced that the United States District Court for the District of New
Jersey has ruled in Eisai's favor with respect to Eisai's motion for a
Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals' Launch of Generic Pantoprazole in Violation of PROTONIX Patent
COLLEGEVILLE, Pa., Dec. 24 /PRNewswire-FirstCall/ -- Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced it will
pursue a patent infringement claim for lost profits and other damages
Pharmaceuticals USA, Inc. resulting from Teva's launch of a
Prix Galien USA Announces 2009 Final Candidates
...is Oncology, GLEEVEC(R)
Novartis Pharmaceuticals, EXELON(R)( )PATCH
Schering-Plough, TEMODAR(R) and ZETIA(R)
Best Biotechnology Product:
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... to $67 million, as a result of the launch by teva
Industries Ltd ("Teva") of a... for the treatment of ADHD
- On April 2, 2009 teva
announced that it had commenced
commercial s...ing the
launch of an authorized generic version by teva
in April 2009. Excluding
ADDERALL XR, product sale...
Sanofi-aventis Announces Second Quarter 2009 Results
...ainst euro 178 million in the first half of 2008, primarily as a result of the royalty equal to 25% of sales of Copaxone((R)) in North America paid by teva
to sanofi-aventis with effect from the second quarter of 2008.
Operating income - current advanced by 20.7% to euro 5,944 million. At constan...
IKARIA(R) to In-License BioLineRx's BL-1040
...ch companies to further the development of promising compounds. The Company was founded in 2003 by leaders in the Israeli life science arena including teva
Pharmaceuticals Ltd., venture capital firms Giza Venture Capital and Pitango Venture Capital, and Hadasit, the technology transfer company of Hadassah...
Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity
KANSAS CITY, Mo., June 9 /PRNewswire/ -- teva
Neuroscience, Inc. today presented results from a ...bjectives," said Jon Congleton, general manager of teva
Neuroscience. "This study provides continuing evid...ults of this study have been submitted to FDA, and teva
Neuroscience intends to work with FDA to appropria...
Teva in Biological Dictionary
... response when the treadmill ... Product Condition: The Uropod Dry Bag - 37L is in Like New condition. ... bombproof waterproof construction, the teva
Uropod Dry Bag stays high and dry on the water. ... The uropod , a protrusion at the rear of amoeboid motile cells such as leukocytes, ... Rem...